Efficacy of early fluid resuscitation combined with Chaiqin Chengqi Decoction in treatment of acute pancreatitis: a randomized controlled trial.

Conditions

acute pancreatitis

Deng L, Chen Z, Jin T, Cai F, He Y, Shen Y, Zhang S, Guo J, Yang X, Yang L, Lu H, Wang C, Tang W, Lin Z, Li L, Tan Q, Zhu P, Zhang X, Shi N, Hu C, Huang Z, Du D, Huang W, Zhang Z, Zhang S, Xia Q, CAP Investigators.

2025-01-239 citations

10.1016/j.phymed.2025.156393

AGI grade-guided chaiqin chengqi decoction treatment for predicted moderately severe and severe acute pancreatitis (CAP trial): study protocol of a randomised, double-blind, placebo-controlled, parallel-group, pragmatic clinical trial

Zhiyao Chen, Xiaonan Yang, Jia Guo, Tao Jin, Ziqi Lin et al. (19 authors)

Trials2022-11-088 citations

10.1186/s13063-022-06792-x

Interventions

treatment group:western treatment+CQCQD (oral, enema)

control group:western treatment+placebo-CQCQD (oral, enema)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years; 2. Meet the diagnostic criteria for AP; 3. Admitted to the Department of Integrated Traditional Chinese and Western Medicine within 72 hours from the onset.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. severe organ dysfunction; 3. HAPS score > 2; 4. Combined with any malignant tumor or history of chemoradiotherapy within 6 months; 5. perforation or bleeding of digestive tract, or intestinal obstruction, etc. which is not suitable for CQCQD administration orally or by enema; 6. acute attack of chronic pancreatitis; 7. any tumor of duodenal, billiary, pancreatic system; 8. history of pancreatectomy; 9. iatrogenic pancreatitis or being received other treatment which potentially interferes the study.

Design outcomes

Primary

Measure	Time frame
cumulative CRP;Duration of respiratory failure;	—

Secondary

Measure	Time frame
PASS score;Consumption of analgesics;clinical scoring system;use of ventilator;length of stay;length of stay in ICU;operation rate;mortality;pancreatic exocrine function;life quality scale;classification of RAC;duration of SIRS;Local pancreatic injury;Useage of CRRT;(Peri)pancreatic infection;	—

Countries

China

Contacts

Public ContactQing Xia

xiaqing@medmail.com.cn+86 18980601723

Outcome results

None listed